Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Ferté · SciRah

Researcher profile · Semantic Scholar

C. Ferté

Share profile

C. Ferté — researcher profile on SciRah

h-index: 32
Works: 135
Citations: 6,937

Most-cited papers

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
S. Champiat, L. Dercle, S. Ammari, C. Massard +7 more
2016Clinical Cancer Research1,084 citations Open access
Semantic Scholar
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
R. Sun, E. Limkin, M. Vakalopoulou, L. Dercle +15 more
2018The Lancet Oncology1,035 citations
Semantic Scholar
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
R. Ferrara, L. Mezquita, M. Texier, J. Lahmar +24 more
2018JAMA Oncology681 citations Open access
Semantic Scholar
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
E. Limkin, R. Sun, L. Dercle, E. Zacharaki +6 more
2017Annals of Oncology674 citations Open access
Semantic Scholar
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
C. Massard, S. Michiels, C. Ferté, M. le Deley +29 more
2017Cancer Discovery667 citations Open access
Semantic Scholar
Hyperprogressive disease: recognizing a novel pattern to improve patient management
S. Champiat, R. Ferrara, C. Massard, B. Besse +3 more
2018Nature Reviews Clinical Oncology338 citations
Semantic Scholar
Tumor Growth Rate (TGR) is an early indicator of anti-tumor drug activity in phase I clinical trials
C. Ferté, Marianna Fernandez, A. Hollebecque, S. Koscielny +8 more
2013Clinical Cancer Research162 citations Open access
Semantic Scholar
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.
L. Verlingue, D. Malka, A. Allorant, C. Massard +15 more
2017European Journal of Cancer151 citations
Semantic Scholar
The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features
E. Limkin, S. Reuzé, A. Carré, R. Sun +5 more
2019Scientific Reports109 citations Open access
Semantic Scholar
Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
C. Jovelet, E. Ileana, M. le Deley, N. Motté +21 more
2016Clinical Cancer Research102 citations
Semantic Scholar
Exomics and immunogenics
S. Champiat, C. Ferté, S. Lebel‐Binay, A. Eggermont +1 more
2014Oncoimmunology99 citations Open access
Semantic Scholar
Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
D. Ou, P. Blanchard, S. Rosellini, A. Lévy +13 more
2017Oral Oncology88 citations Open access
Semantic Scholar
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
C. Ferté, S. Koscielny, L. Albiges, L. Rocher +5 more
2014European Urology84 citations
Semantic Scholar
Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells
R. Sun, N. Sundahl, M. Hecht, F. Putz +24 more
2020Journal for ImmunoTherapy of Cancer83 citations Open access
Semantic Scholar
Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence
L. Dercle, S. Ammari, M. Bateson, P. Durand +7 more
2017Scientific Reports80 citations Open access
Semantic Scholar
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
A. Hollebecque, D. Malka, C. Ferté, M. Ducreux +1 more
2015European Journal of Cancer67 citations
Semantic Scholar
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
C. Even, U. Lassen, J. Merchan, C. le Tourneau +9 more
2019Investigational new drugs66 citations Open access
Semantic Scholar
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.
L. Dercle, S. Ammari, S. Champiat, C. Massard +11 more
2016European Journal of Cancer66 citations
Semantic Scholar
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
L. Claret, Jin Y. Jin, C. Ferté, H. Winter +10 more
2018Clinical Cancer Research64 citations Open access
Semantic Scholar
Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review
J. Bibault, I. Fumagalli, C. Ferté, Cyrus Chargari +2 more
2013Cancer Metastasis Review57 citations
Semantic Scholar
TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen
A. Marquard, N. Birkbak, C. E. Thomas, F. Favero +10 more
2015BMC Medical Genomics55 citations Open access
Semantic Scholar
Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).
V. Tacher, M. le Deley, A. Hollebecque, F. Deschamps +19 more
2016European Journal of Cancer45 citations
Semantic Scholar
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
L. Siu, J. Brody, Shilpa Gupta, A. Marabelle +15 more
2020Journal for ImmunoTherapy of Cancer41 citations Open access
Semantic Scholar
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
R. Sun, S. Champiat, L. Dercle, S. Aspeslagh +11 more
2017European Journal of Cancer39 citations
Semantic Scholar
Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in Oncology
C. Ferté, Andrew D. Trister, Erich Huang, B. Bot +7 more
2013Clinical Cancer Research39 citations Open access
Semantic Scholar
Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?
H. Mirghani, L. Lacroix, C. Rossoni, R. Sun +9 more
2018European Journal of Cancer38 citations
Semantic Scholar
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.
R. Ferrara, L. Mezquita, M. Texier, J. Lahmar +25 more
2020JCO Precision Oncology32 citations Open access
Semantic Scholar
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
P. Martin-Romano, E. Castañón, S. Ammari, S. Champiat +10 more
2020Cancer Medicine31 citations Open access
Semantic Scholar
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
J. Soria, A. Adjei, R. Bahleda, B. Besse +10 more
2017European Journal of Cancer31 citations Open access
Semantic Scholar
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
L. Verlingue, A. Hollebecque, V. Boige, M. Ducreux +2 more
2017European Journal of Cancer30 citations
Semantic Scholar
iRECIST: A clarification of tumour response assessment in the immunotherapy era.
C. Ferté, A. Marabelle
2017European Journal of Cancer30 citations
Semantic Scholar
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
C. Clémenson, C. Chargari, Winchygn Liu, M. Mondini +5 more
2017Molecular Cancer Therapeutics30 citations Open access
Semantic Scholar
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.
C. Massard, I. Borget, F. Farace, S. Aspeslagh +10 more
2017European Journal of Cancer22 citations
Semantic Scholar
rCGH: a comprehensive array-based genomic profile platform for precision medicine
F. Commo, J. Guinney, C. Ferté, B. Bot +3 more
2015Bioinform.19 citations Open access
Semantic Scholar
Tumor assessment criteria in phase I trials: beyond RECIST.
A. Lévy, A. Hollebecque, C. Ferté, S. Koscielny +3 more
2013Journal of Clinical Oncology17 citations Open access
Semantic Scholar
Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology.
F. Commo, C. Ferté, J. Soria, S. Friend +2 more
2015Annals of Oncology16 citations Open access
Semantic Scholar
Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients
C. Ferté, C. Massard, E. Ileana, A. Hollebecque +24 more
201416 citations
Semantic Scholar
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
S. Berry, Nicolas A. Giraldo, Peter Nguyen, B. Green +87 more
2019Journal of Immunotherapy for Cancer14 citations Open access
Semantic Scholar
Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma.
P. Gorphe, M. Matias, C. Even, C. Ferté +7 more
2016Anticancer Research12 citations Open access
Semantic Scholar
High incidence of cetuximab-related infusion reactions in head and neck patients
Virginia Palomar Coloma, P. Bravo, N. Lezghed, L. Mayache-Badis +11 more
2018ESMO Open11 citations Open access
Semantic Scholar
Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).
J. Lahmar, F. Facchinetti, S. Koscielny, C. Ferté +8 more
201611 citations
Semantic Scholar
Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy
P. Gorphe, M. Matias, P. Blanchard, C. Even +5 more
2017The Laryngoscope9 citations
Semantic Scholar
Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC).
C. Even, U. Lassen, J. Merchan, C. le Tourneau +8 more
20178 citations
Semantic Scholar
3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC)
C. Caramella, M. Bluthgen, S. Rosellini, C. Leduc +6 more
20158 citations
Semantic Scholar
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors
B. Tran, M. Voskoboynik, J. Bendell, M. Gutierrez +10 more
2024Immunotherapy7 citations Open access
Semantic Scholar
Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors
L. Goyal, M. Borad, V. Subbiah, A. Mahipal +17 more
2021Oral Presentations - Late-Breaking Proffered Abstracts7 citations
Semantic Scholar
Preliminary Results From a Phase 2 Trial of Tipifarnib in HRAS-Mutant Head and Neck Squamous Cell Carcinomas
A. Ho, N. Chau, I. Garcia, C. Ferté +7 more
20187 citations
Semantic Scholar
Abstract LB-A10: Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations
A. Ho, N. Chau, D. Wong, M. Cabanillas +13 more
20185 citations
Semantic Scholar
MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO)
R. Ferrara, C. Caramella, M. Texier, C. Audigier-Valette +21 more
20175 citations Open access
Semantic Scholar
Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial
E. Ileana, C. Jovelet, M. le Deley, C. Massard +21 more
20154 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Soria×32
Invite
J. Soria — researcher profile on SciRah
C. Massard×19
Invite
C. Massard — researcher profile on SciRah
A. Hollebecque×15
Invite
A. Hollebecque — researcher profile on SciRah
S. Champiat×10
Invite
S. Champiat — researcher profile on SciRah

×9

Invite

S. Ammari — researcher profile on SciRah

Invite

C. Even — researcher profile on SciRah

Invite

F. André — researcher profile on SciRah

S. Postel-Vinay×8

Invite

S. Postel-Vinay — researcher profile on SciRah

A. Marabelle×8

Invite

A. Marabelle — researcher profile on SciRah

Invite

E. Deutsch — researcher profile on SciRah

Invite

B. Besse — researcher profile on SciRah

Invite

L. Lacroix — researcher profile on SciRah